Bioheart, a biotech company engaged in the development of autologous cell therapies for the treatment of chronic and acute heart damage, amended the terms for its planned IPO on Thursday. While the company now plans to offer roughly 4.2 million shares vs. 3.6 million shares as originally planned, it slashed its proposed price range from $14-$16 to $6-$8, according to the latest SEC filing. Timing for the IPO was pushed back to the week of October 22 by lead underwriter Merriman Curhan Ford & Co.
